| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Malaria | 19 | 2025 | 147 | 6.700 |
Why?
|
| Trypanosoma cruzi | 28 | 2022 | 52 | 4.800 |
Why?
|
| Malaria, Vivax | 14 | 2025 | 48 | 4.300 |
Why?
|
| Plasmodium vivax | 14 | 2025 | 46 | 3.820 |
Why?
|
| CD8-Positive T-Lymphocytes | 23 | 2022 | 674 | 3.730 |
Why?
|
| Antigens, Protozoan | 14 | 2025 | 56 | 3.590 |
Why?
|
| Toxoplasma | 10 | 2025 | 33 | 3.060 |
Why?
|
| Chagas Disease | 19 | 2022 | 36 | 2.910 |
Why?
|
| Host-Parasite Interactions | 14 | 2025 | 58 | 2.880 |
Why?
|
| Immunity, Innate | 16 | 2025 | 795 | 2.730 |
Why?
|
| Interferon-gamma | 20 | 2025 | 567 | 2.680 |
Why?
|
| Toxoplasmosis | 8 | 2025 | 20 | 2.620 |
Why?
|
| Plasmodium | 5 | 2025 | 33 | 2.540 |
Why?
|
| Plasmodium chabaudi | 7 | 2025 | 29 | 2.370 |
Why?
|
| Leishmaniasis, Visceral | 7 | 2025 | 14 | 2.360 |
Why?
|
| Monocytes | 11 | 2024 | 353 | 2.360 |
Why?
|
| Dendritic Cells | 9 | 2024 | 524 | 2.360 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 4 | 2024 | 34 | 2.240 |
Why?
|
| Malaria, Cerebral | 4 | 2020 | 23 | 2.180 |
Why?
|
| Protozoan Vaccines | 10 | 2021 | 14 | 1.970 |
Why?
|
| Leishmania infantum | 6 | 2025 | 8 | 1.960 |
Why?
|
| Toll-Like Receptors | 9 | 2020 | 431 | 1.910 |
Why?
|
| Mice | 61 | 2025 | 10809 | 1.840 |
Why?
|
| Animals | 73 | 2025 | 20591 | 1.670 |
Why?
|
| Leishmaniasis Vaccines | 3 | 2025 | 3 | 1.650 |
Why?
|
| Cancer Vaccines | 4 | 2014 | 49 | 1.640 |
Why?
|
| Protozoan Proteins | 9 | 2025 | 126 | 1.570 |
Why?
|
| Cytokines | 15 | 2023 | 931 | 1.570 |
Why?
|
| Inflammation | 10 | 2023 | 1140 | 1.560 |
Why?
|
| Neutrophils | 4 | 2021 | 376 | 1.460 |
Why?
|
| Anopheles | 5 | 2023 | 21 | 1.460 |
Why?
|
| Leishmania | 3 | 2025 | 12 | 1.440 |
Why?
|
| Plasmodium berghei | 3 | 2019 | 21 | 1.380 |
Why?
|
| Antibodies, Protozoan | 13 | 2025 | 52 | 1.370 |
Why?
|
| Circadian Rhythm | 3 | 2025 | 380 | 1.290 |
Why?
|
| Vaccines, Synthetic | 8 | 2025 | 72 | 1.270 |
Why?
|
| Antigens, Neoplasm | 4 | 2014 | 136 | 1.260 |
Why?
|
| Antibodies, Viral | 6 | 2025 | 321 | 1.260 |
Why?
|
| Cytotoxicity, Immunologic | 4 | 2025 | 149 | 1.250 |
Why?
|
| Toll-Like Receptor 9 | 7 | 2014 | 210 | 1.230 |
Why?
|
| Antibodies, Neutralizing | 5 | 2025 | 208 | 1.230 |
Why?
|
| Mice, Inbred C57BL | 29 | 2025 | 3388 | 1.210 |
Why?
|
| Myeloid Differentiation Factor 88 | 4 | 2022 | 203 | 1.180 |
Why?
|
| Malaria, Falciparum | 5 | 2021 | 220 | 1.130 |
Why?
|
| Toll-Like Receptor 7 | 3 | 2013 | 102 | 1.110 |
Why?
|
| Mice, Knockout | 20 | 2025 | 2106 | 1.100 |
Why?
|
| Adaptive Immunity | 3 | 2025 | 101 | 1.060 |
Why?
|
| Membrane Transport Proteins | 3 | 2013 | 133 | 1.050 |
Why?
|
| DNA, Protozoan | 7 | 2015 | 50 | 1.040 |
Why?
|
| Humans | 75 | 2025 | 63051 | 1.010 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 4 | 2021 | 109 | 1.000 |
Why?
|
| Toxoplasmosis, Ocular | 4 | 2025 | 7 | 0.980 |
Why?
|
| Spleen | 9 | 2020 | 482 | 0.940 |
Why?
|
| Membrane Proteins | 6 | 2017 | 893 | 0.910 |
Why?
|
| Succinates | 1 | 2024 | 9 | 0.880 |
Why?
|
| Energy Metabolism | 2 | 2025 | 377 | 0.880 |
Why?
|
| Hypoglycemia | 2 | 2022 | 67 | 0.880 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2023 | 428 | 0.870 |
Why?
|
| Tumor Necrosis Factor-alpha | 5 | 2025 | 613 | 0.830 |
Why?
|
| Reticulocytes | 3 | 2021 | 12 | 0.820 |
Why?
|
| Superinfection | 1 | 2022 | 10 | 0.800 |
Why?
|
| Coinfection | 2 | 2022 | 59 | 0.800 |
Why?
|
| Mice, Inbred BALB C | 10 | 2025 | 892 | 0.800 |
Why?
|
| Toxoplasmosis, Animal | 2 | 2014 | 10 | 0.790 |
Why?
|
| Acidosis, Lactic | 1 | 2022 | 11 | 0.780 |
Why?
|
| Inflammasomes | 5 | 2023 | 331 | 0.770 |
Why?
|
| Serologic Tests | 3 | 2025 | 37 | 0.770 |
Why?
|
| Erythrocytes | 5 | 2021 | 149 | 0.760 |
Why?
|
| CD4-Positive T-Lymphocytes | 10 | 2025 | 641 | 0.750 |
Why?
|
| Interleukin-12 | 5 | 2024 | 127 | 0.740 |
Why?
|
| Plasmodium falciparum | 5 | 2021 | 246 | 0.730 |
Why?
|
| Chagas Cardiomyopathy | 5 | 2021 | 7 | 0.730 |
Why?
|
| Extracellular Traps | 1 | 2021 | 43 | 0.720 |
Why?
|
| Leishmaniasis | 3 | 2016 | 10 | 0.710 |
Why?
|
| Female | 42 | 2025 | 32755 | 0.700 |
Why?
|
| Plasmodium yoelii | 1 | 2020 | 6 | 0.700 |
Why?
|
| Gene Expression Regulation | 7 | 2021 | 1616 | 0.700 |
Why?
|
| Toll-Like Receptor 3 | 3 | 2022 | 66 | 0.690 |
Why?
|
| Caspase 8 | 1 | 2020 | 64 | 0.670 |
Why?
|
| Mitochondria | 3 | 2024 | 370 | 0.660 |
Why?
|
| Membrane Glycoproteins | 3 | 2013 | 668 | 0.650 |
Why?
|
| Disease Models, Animal | 10 | 2025 | 2177 | 0.650 |
Why?
|
| Immunity | 2 | 2020 | 106 | 0.640 |
Why?
|
| Immunization, Secondary | 4 | 2025 | 44 | 0.640 |
Why?
|
| Lymphocyte Activation | 8 | 2021 | 758 | 0.630 |
Why?
|
| T-Lymphocytes | 5 | 2025 | 1003 | 0.620 |
Why?
|
| Spike Glycoprotein, Coronavirus | 3 | 2025 | 113 | 0.620 |
Why?
|
| Receptors, Immunologic | 2 | 2014 | 177 | 0.620 |
Why?
|
| Signal Transduction | 6 | 2023 | 3023 | 0.620 |
Why?
|
| Caspase 1 | 3 | 2020 | 111 | 0.610 |
Why?
|
| Receptors, CCR4 | 1 | 2018 | 4 | 0.610 |
Why?
|
| Brazil | 9 | 2025 | 98 | 0.610 |
Why?
|
| Th2 Cells | 1 | 2018 | 98 | 0.590 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2018 | 70 | 0.590 |
Why?
|
| Adenoviridae | 6 | 2015 | 121 | 0.570 |
Why?
|
| Flow Cytometry | 7 | 2019 | 669 | 0.550 |
Why?
|
| Leishmania major | 2 | 2016 | 8 | 0.540 |
Why?
|
| Vaccination | 7 | 2022 | 356 | 0.530 |
Why?
|
| Immunization | 4 | 2021 | 133 | 0.530 |
Why?
|
| Immunity, Cellular | 3 | 2018 | 175 | 0.530 |
Why?
|
| Inflammation Mediators | 3 | 2020 | 176 | 0.500 |
Why?
|
| Antigen-Antibody Complex | 1 | 2015 | 52 | 0.490 |
Why?
|
| Receptors, IgG | 2 | 2021 | 41 | 0.490 |
Why?
|
| Granulocytes | 1 | 2015 | 71 | 0.490 |
Why?
|
| Malaria Vaccines | 3 | 2024 | 37 | 0.490 |
Why?
|
| Receptors, CXCR3 | 3 | 2020 | 35 | 0.490 |
Why?
|
| Lipopolysaccharide Receptors | 2 | 2021 | 144 | 0.480 |
Why?
|
| Transcription, Genetic | 2 | 2018 | 873 | 0.480 |
Why?
|
| Th1 Cells | 5 | 2025 | 175 | 0.480 |
Why?
|
| Immunogenicity, Vaccine | 2 | 2025 | 16 | 0.480 |
Why?
|
| Leishmania donovani | 2 | 2012 | 4 | 0.470 |
Why?
|
| Melanoma, Experimental | 2 | 2014 | 44 | 0.470 |
Why?
|
| CTLA-4 Antigen | 1 | 2014 | 71 | 0.460 |
Why?
|
| Nanotubes, Carbon | 1 | 2014 | 19 | 0.450 |
Why?
|
| Male | 28 | 2025 | 29773 | 0.450 |
Why?
|
| Interferon Type I | 2 | 2015 | 184 | 0.450 |
Why?
|
| Biological Evolution | 2 | 2020 | 120 | 0.440 |
Why?
|
| Leishmaniasis, Cutaneous | 2 | 2016 | 16 | 0.440 |
Why?
|
| Parasitemia | 6 | 2025 | 47 | 0.440 |
Why?
|
| Interleukin-10 | 4 | 2025 | 160 | 0.440 |
Why?
|
| Epitopes, B-Lymphocyte | 2 | 2011 | 18 | 0.430 |
Why?
|
| Brain | 3 | 2020 | 1552 | 0.430 |
Why?
|
| Interleukin-12 Subunit p40 | 3 | 2021 | 17 | 0.420 |
Why?
|
| Parasites | 3 | 2022 | 16 | 0.420 |
Why?
|
| Nucleic Acids | 2 | 2013 | 60 | 0.420 |
Why?
|
| Adjuvants, Immunologic | 6 | 2025 | 229 | 0.410 |
Why?
|
| Nanotechnology | 1 | 2014 | 135 | 0.410 |
Why?
|
| Asymptomatic Infections | 2 | 2025 | 29 | 0.410 |
Why?
|
| Carrier Proteins | 3 | 2014 | 703 | 0.410 |
Why?
|
| Cells, Cultured | 8 | 2021 | 2152 | 0.400 |
Why?
|
| Toxoplasmosis, Congenital | 1 | 2012 | 4 | 0.400 |
Why?
|
| Nod2 Signaling Adaptor Protein | 1 | 2012 | 26 | 0.400 |
Why?
|
| Interleukin-1beta | 5 | 2020 | 260 | 0.400 |
Why?
|
| Immunophenotyping | 5 | 2018 | 193 | 0.390 |
Why?
|
| Bacterial Infections | 1 | 2014 | 148 | 0.390 |
Why?
|
| Immunotherapy | 1 | 2014 | 251 | 0.390 |
Why?
|
| Drug Carriers | 1 | 2014 | 179 | 0.380 |
Why?
|
| Interleukin-17 | 1 | 2012 | 94 | 0.380 |
Why?
|
| Phagocytosis | 4 | 2021 | 264 | 0.370 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2014 | 336 | 0.370 |
Why?
|
| Vaccines | 2 | 2023 | 96 | 0.360 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2011 | 39 | 0.360 |
Why?
|
| Hydrocarbons, Aromatic | 1 | 2011 | 2 | 0.360 |
Why?
|
| Orthomyxoviridae | 2 | 2013 | 25 | 0.360 |
Why?
|
| Iron | 2 | 2022 | 146 | 0.350 |
Why?
|
| Cell Differentiation | 5 | 2021 | 1350 | 0.350 |
Why?
|
| Adult | 17 | 2025 | 16658 | 0.350 |
Why?
|
| Chemokines | 2 | 2021 | 95 | 0.340 |
Why?
|
| Young Adult | 10 | 2025 | 4646 | 0.340 |
Why?
|
| Disease Susceptibility | 3 | 2019 | 166 | 0.330 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2012 | 496 | 0.330 |
Why?
|
| Immunoglobulin G | 6 | 2025 | 466 | 0.320 |
Why?
|
| Genetic Vectors | 6 | 2014 | 853 | 0.320 |
Why?
|
| Antigens, CD | 3 | 2021 | 348 | 0.320 |
Why?
|
| Chromatography, Affinity | 3 | 2025 | 48 | 0.320 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 6 | 2025 | 452 | 0.310 |
Why?
|
| Cell Separation | 3 | 2019 | 147 | 0.310 |
Why?
|
| Orthomyxoviridae Infections | 2 | 2025 | 71 | 0.310 |
Why?
|
| Proteomics | 1 | 2011 | 284 | 0.310 |
Why?
|
| Disease Resistance | 3 | 2013 | 24 | 0.310 |
Why?
|
| Neuraminidase | 5 | 2022 | 43 | 0.300 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2023 | 241 | 0.300 |
Why?
|
| Epitope Mapping | 1 | 2008 | 50 | 0.300 |
Why?
|
| Hemeproteins | 3 | 2014 | 16 | 0.290 |
Why?
|
| NF-kappa B | 2 | 2018 | 469 | 0.290 |
Why?
|
| Dog Diseases | 1 | 2008 | 60 | 0.280 |
Why?
|
| Lysosomes | 1 | 2008 | 167 | 0.280 |
Why?
|
| Dogs | 4 | 2019 | 319 | 0.270 |
Why?
|
| Protozoan Infections | 1 | 2006 | 3 | 0.270 |
Why?
|
| Macrophages, Peritoneal | 3 | 2021 | 77 | 0.260 |
Why?
|
| Eukaryota | 1 | 2006 | 29 | 0.260 |
Why?
|
| Middle Aged | 13 | 2025 | 17605 | 0.250 |
Why?
|
| Pneumococcal Vaccines | 1 | 2025 | 20 | 0.240 |
Why?
|
| Hepatitis D | 1 | 2025 | 2 | 0.240 |
Why?
|
| Pneumococcal Infections | 1 | 2025 | 38 | 0.240 |
Why?
|
| Hepatitis Antibodies | 1 | 2025 | 6 | 0.240 |
Why?
|
| Hepatitis Delta Virus | 1 | 2025 | 3 | 0.240 |
Why?
|
| Orthobunyavirus | 1 | 2025 | 1 | 0.240 |
Why?
|
| Bunyaviridae Infections | 1 | 2025 | 2 | 0.240 |
Why?
|
| Liver | 3 | 2018 | 847 | 0.240 |
Why?
|
| Macrophages | 4 | 2016 | 1035 | 0.240 |
Why?
|
| Travel | 1 | 2025 | 42 | 0.230 |
Why?
|
| Point-of-Care Testing | 1 | 2025 | 43 | 0.230 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 2 | 2017 | 111 | 0.230 |
Why?
|
| Viral Vaccines | 2 | 2022 | 49 | 0.230 |
Why?
|
| Recombinant Proteins | 4 | 2025 | 701 | 0.230 |
Why?
|
| Heart | 3 | 2021 | 282 | 0.230 |
Why?
|
| Influenza Vaccines | 1 | 2025 | 97 | 0.220 |
Why?
|
| Carboxymethylcellulose Sodium | 1 | 2024 | 7 | 0.220 |
Why?
|
| Myocardium | 2 | 2019 | 275 | 0.220 |
Why?
|
| RNA, Protozoan | 2 | 2014 | 10 | 0.220 |
Why?
|
| Interferon Regulatory Factors | 1 | 2024 | 43 | 0.220 |
Why?
|
| Cricetinae | 1 | 2024 | 368 | 0.220 |
Why?
|
| Neoplasms | 1 | 2014 | 1348 | 0.210 |
Why?
|
| Antigens, Differentiation | 1 | 2004 | 137 | 0.210 |
Why?
|
| Toll-Like Receptor 4 | 2 | 2022 | 344 | 0.210 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2025 | 495 | 0.210 |
Why?
|
| Polylysine | 1 | 2024 | 49 | 0.210 |
Why?
|
| B7-H1 Antigen | 1 | 2024 | 56 | 0.210 |
Why?
|
| Cell Death | 2 | 2022 | 283 | 0.210 |
Why?
|
| DNA, Mitochondrial | 1 | 2024 | 87 | 0.210 |
Why?
|
| Lipopolysaccharides | 2 | 2020 | 643 | 0.210 |
Why?
|
| Acute Disease | 4 | 2020 | 669 | 0.200 |
Why?
|
| Mice, Transgenic | 2 | 2024 | 1271 | 0.200 |
Why?
|
| Kupffer Cells | 1 | 2022 | 43 | 0.200 |
Why?
|
| Nucleocapsid | 1 | 2022 | 12 | 0.200 |
Why?
|
| Chemotaxis, Leukocyte | 2 | 2020 | 62 | 0.200 |
Why?
|
| Gluconeogenesis | 1 | 2022 | 15 | 0.200 |
Why?
|
| Nucleocapsid Proteins | 1 | 2022 | 36 | 0.200 |
Why?
|
| Adolescent | 7 | 2025 | 6189 | 0.200 |
Why?
|
| Lipids | 1 | 2025 | 316 | 0.200 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2022 | 81 | 0.190 |
Why?
|
| Antimalarials | 1 | 2023 | 124 | 0.190 |
Why?
|
| B-Lymphocytes | 2 | 2017 | 569 | 0.190 |
Why?
|
| Vaccines, Inactivated | 1 | 2021 | 12 | 0.190 |
Why?
|
| Blood | 1 | 2021 | 30 | 0.190 |
Why?
|
| Cell Phone | 1 | 2022 | 43 | 0.190 |
Why?
|
| Cell Proliferation | 3 | 2018 | 978 | 0.190 |
Why?
|
| GPI-Linked Proteins | 1 | 2021 | 41 | 0.180 |
Why?
|
| Interleukins | 1 | 2021 | 80 | 0.180 |
Why?
|
| Shock, Septic | 2 | 2014 | 86 | 0.180 |
Why?
|
| RNA, Messenger | 2 | 2025 | 1535 | 0.180 |
Why?
|
| Cell Adhesion Molecules | 1 | 2021 | 90 | 0.180 |
Why?
|
| Seasons | 1 | 2021 | 133 | 0.180 |
Why?
|
| Cohort Studies | 2 | 2021 | 2763 | 0.180 |
Why?
|
| Enterobacteriaceae Infections | 1 | 2021 | 11 | 0.180 |
Why?
|
| Intraepithelial Lymphocytes | 1 | 2021 | 8 | 0.180 |
Why?
|
| Chorioretinitis | 1 | 2020 | 1 | 0.180 |
Why?
|
| Pore Forming Cytotoxic Proteins | 2 | 2012 | 34 | 0.180 |
Why?
|
| Lymphocyte Count | 2 | 2018 | 72 | 0.180 |
Why?
|
| Rats | 1 | 2024 | 1978 | 0.170 |
Why?
|
| CpG Islands | 2 | 2014 | 217 | 0.170 |
Why?
|
| Neutrophil Activation | 1 | 2020 | 24 | 0.170 |
Why?
|
| Severe Acute Respiratory Syndrome | 1 | 2020 | 24 | 0.170 |
Why?
|
| Societies, Scientific | 1 | 2020 | 36 | 0.170 |
Why?
|
| Granzymes | 2 | 2021 | 21 | 0.170 |
Why?
|
| Chemokine CCL3 | 1 | 2020 | 9 | 0.170 |
Why?
|
| International Cooperation | 1 | 2020 | 89 | 0.170 |
Why?
|
| Multimodal Imaging | 1 | 2020 | 67 | 0.170 |
Why?
|
| Disease Outbreaks | 1 | 2020 | 115 | 0.170 |
Why?
|
| Blotting, Western | 2 | 2011 | 607 | 0.170 |
Why?
|
| Allergy and Immunology | 1 | 2019 | 8 | 0.160 |
Why?
|
| Enzyme Activation | 1 | 2020 | 380 | 0.160 |
Why?
|
| Adenovirus Vaccines | 1 | 2019 | 1 | 0.160 |
Why?
|
| Blood Glucose | 1 | 2022 | 483 | 0.160 |
Why?
|
| Intestines | 1 | 2021 | 166 | 0.160 |
Why?
|
| Extracellular Matrix | 1 | 2020 | 139 | 0.160 |
Why?
|
| Gene Regulatory Networks | 1 | 2020 | 158 | 0.150 |
Why?
|
| Antigens | 2 | 2022 | 147 | 0.150 |
Why?
|
| Nanoparticles | 1 | 2025 | 517 | 0.150 |
Why?
|
| Trophozoites | 1 | 2018 | 6 | 0.150 |
Why?
|
| Fibroblasts | 1 | 2020 | 392 | 0.150 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2018 | 63 | 0.150 |
Why?
|
| Reactive Oxygen Species | 2 | 2021 | 221 | 0.150 |
Why?
|
| HLA Antigens | 1 | 2018 | 63 | 0.150 |
Why?
|
| Carbohydrate Metabolism | 1 | 2018 | 49 | 0.150 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 545 | 0.150 |
Why?
|
| RNA-Binding Proteins | 2 | 2018 | 434 | 0.140 |
Why?
|
| Mosquito Vectors | 3 | 2022 | 13 | 0.140 |
Why?
|
| Leukocytes | 1 | 2018 | 105 | 0.140 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 3 | 2014 | 255 | 0.140 |
Why?
|
| Eating | 1 | 2018 | 137 | 0.140 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 206 | 0.140 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 220 | 0.140 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2018 | 199 | 0.140 |
Why?
|
| Genotype | 2 | 2025 | 665 | 0.140 |
Why?
|
| Chemokine CXCL9 | 1 | 2016 | 24 | 0.130 |
Why?
|
| Survival Analysis | 3 | 2021 | 579 | 0.130 |
Why?
|
| Chemokine CXCL10 | 1 | 2016 | 58 | 0.130 |
Why?
|
| CD36 Antigens | 1 | 2016 | 26 | 0.130 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2018 | 212 | 0.130 |
Why?
|
| Receptors, CCR5 | 1 | 2016 | 59 | 0.130 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2016 | 41 | 0.130 |
Why?
|
| Cell Cycle | 1 | 2018 | 393 | 0.130 |
Why?
|
| Perforin | 1 | 2016 | 31 | 0.130 |
Why?
|
| Gene Expression Profiling | 4 | 2017 | 767 | 0.120 |
Why?
|
| Phenotype | 3 | 2019 | 1195 | 0.120 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2016 | 126 | 0.120 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinases | 1 | 2016 | 81 | 0.120 |
Why?
|
| Pandemics | 1 | 2020 | 661 | 0.120 |
Why?
|
| Endocytosis | 1 | 2016 | 152 | 0.120 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2016 | 174 | 0.120 |
Why?
|
| Glucose | 1 | 2018 | 469 | 0.120 |
Why?
|
| Protein Multimerization | 1 | 2015 | 173 | 0.120 |
Why?
|
| Sensitivity and Specificity | 3 | 2025 | 1140 | 0.110 |
Why?
|
| Parasite Load | 1 | 2014 | 4 | 0.110 |
Why?
|
| Adenoviruses, Human | 1 | 2014 | 9 | 0.110 |
Why?
|
| Spectrum Analysis, Raman | 1 | 2014 | 23 | 0.110 |
Why?
|
| Mice, Mutant Strains | 2 | 2016 | 302 | 0.110 |
Why?
|
| Killer Cells, Natural | 1 | 2016 | 217 | 0.110 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 2556 | 0.110 |
Why?
|
| Macaca | 1 | 2014 | 32 | 0.110 |
Why?
|
| Calibration | 1 | 2014 | 67 | 0.110 |
Why?
|
| Immune Tolerance | 1 | 2015 | 175 | 0.110 |
Why?
|
| Microscopy, Confocal | 2 | 2016 | 234 | 0.110 |
Why?
|
| Insulin | 1 | 2018 | 686 | 0.110 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2014 | 135 | 0.110 |
Why?
|
| Anticarcinogenic Agents | 1 | 2014 | 78 | 0.110 |
Why?
|
| Cats | 1 | 2014 | 87 | 0.110 |
Why?
|
| Up-Regulation | 2 | 2019 | 375 | 0.110 |
Why?
|
| Glycosylphosphatidylinositols | 1 | 2013 | 24 | 0.110 |
Why?
|
| Biosynthetic Pathways | 1 | 2013 | 18 | 0.110 |
Why?
|
| Insect Vectors | 1 | 2013 | 15 | 0.110 |
Why?
|
| Lymphocytes | 1 | 2014 | 200 | 0.100 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2015 | 287 | 0.100 |
Why?
|
| Chronic Disease | 3 | 2025 | 751 | 0.100 |
Why?
|
| Genome, Insect | 1 | 2013 | 31 | 0.100 |
Why?
|
| Peru | 2 | 2022 | 14 | 0.100 |
Why?
|
| Host-Pathogen Interactions | 1 | 2015 | 263 | 0.100 |
Why?
|
| Dimerization | 1 | 2013 | 145 | 0.100 |
Why?
|
| Oxygen | 1 | 2014 | 315 | 0.100 |
Why?
|
| G-Protein-Coupled Receptor Kinase 2 | 1 | 2012 | 5 | 0.100 |
Why?
|
| Computational Biology | 2 | 2013 | 354 | 0.100 |
Why?
|
| Th17 Cells | 1 | 2012 | 61 | 0.100 |
Why?
|
| Superoxides | 1 | 2012 | 71 | 0.100 |
Why?
|
| Aged | 4 | 2021 | 14268 | 0.100 |
Why?
|
| Haplotypes | 1 | 2012 | 130 | 0.100 |
Why?
|
| Chemotaxis | 1 | 2012 | 49 | 0.100 |
Why?
|
| CD4 Antigens | 1 | 2013 | 149 | 0.100 |
Why?
|
| Toll-Like Receptor 2 | 2 | 2021 | 223 | 0.100 |
Why?
|
| Cytoskeletal Proteins | 1 | 2013 | 197 | 0.100 |
Why?
|
| fas Receptor | 1 | 2012 | 57 | 0.090 |
Why?
|
| Immunologic Memory | 1 | 2014 | 288 | 0.090 |
Why?
|
| Epitopes, T-Lymphocyte | 2 | 2013 | 181 | 0.090 |
Why?
|
| AT Rich Sequence | 1 | 2011 | 5 | 0.090 |
Why?
|
| Neoplasms, Experimental | 1 | 2011 | 77 | 0.090 |
Why?
|
| Child, Preschool | 2 | 2018 | 1969 | 0.090 |
Why?
|
| Macaca mulatta | 1 | 2012 | 249 | 0.090 |
Why?
|
| Child | 3 | 2020 | 4479 | 0.090 |
Why?
|
| Alleles | 1 | 2012 | 450 | 0.090 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2011 | 84 | 0.090 |
Why?
|
| Immunoassay | 1 | 2011 | 70 | 0.090 |
Why?
|
| Virulence Factors | 2 | 2022 | 85 | 0.090 |
Why?
|
| Peptides | 1 | 2014 | 576 | 0.090 |
Why?
|
| Blood-Brain Barrier | 1 | 2011 | 85 | 0.080 |
Why?
|
| Species Specificity | 1 | 2011 | 336 | 0.080 |
Why?
|
| Vaccines, DNA | 3 | 2019 | 97 | 0.080 |
Why?
|
| Immunoblotting | 1 | 2010 | 204 | 0.080 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2010 | 231 | 0.080 |
Why?
|
| Macrophage Activation | 1 | 2010 | 119 | 0.080 |
Why?
|
| Antigen-Presenting Cells | 1 | 2010 | 178 | 0.080 |
Why?
|
| Transfection | 1 | 2011 | 691 | 0.080 |
Why?
|
| Oligonucleotides | 1 | 2011 | 219 | 0.080 |
Why?
|
| Nuclear Proteins | 1 | 2014 | 773 | 0.080 |
Why?
|
| Phylogeny | 2 | 2025 | 374 | 0.080 |
Why?
|
| Fever | 1 | 2009 | 66 | 0.080 |
Why?
|
| Glycoproteins | 2 | 2022 | 187 | 0.080 |
Why?
|
| Leukocyte Count | 1 | 2008 | 96 | 0.070 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 2008 | 30 | 0.070 |
Why?
|
| Melanoma | 1 | 2012 | 331 | 0.070 |
Why?
|
| Retroelements | 1 | 2008 | 45 | 0.070 |
Why?
|
| Cell Line | 2 | 2013 | 2030 | 0.070 |
Why?
|
| Bone Marrow Cells | 1 | 2008 | 238 | 0.070 |
Why?
|
| Cell Line, Tumor | 1 | 2011 | 1457 | 0.070 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2008 | 244 | 0.070 |
Why?
|
| Genes, Protozoan | 2 | 2017 | 14 | 0.060 |
Why?
|
| Vaccines, Combined | 1 | 2025 | 9 | 0.060 |
Why?
|
| Injections, Intramuscular | 1 | 2025 | 71 | 0.060 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2025 | 93 | 0.060 |
Why?
|
| Hepatitis delta Antigens | 1 | 2025 | 2 | 0.060 |
Why?
|
| Streptococcus pneumoniae | 1 | 2025 | 66 | 0.060 |
Why?
|
| Travel-Related Illness | 1 | 2025 | 4 | 0.060 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2025 | 18 | 0.060 |
Why?
|
| Sepsis | 1 | 2009 | 279 | 0.060 |
Why?
|
| Time Factors | 1 | 2013 | 3744 | 0.060 |
Why?
|
| Antigen Presentation | 1 | 2007 | 237 | 0.060 |
Why?
|
| Amino Acid Sequence | 1 | 2008 | 1593 | 0.060 |
Why?
|
| Molecular Sequence Data | 1 | 2008 | 1996 | 0.060 |
Why?
|
| Liposomes | 1 | 2025 | 105 | 0.060 |
Why?
|
| Cell Movement | 2 | 2020 | 447 | 0.060 |
Why?
|
| Tissue Distribution | 1 | 2025 | 293 | 0.060 |
Why?
|
| Antibodies, Bacterial | 1 | 2025 | 193 | 0.060 |
Why?
|
| Models, Molecular | 1 | 2008 | 1142 | 0.060 |
Why?
|
| Reactive Nitrogen Species | 1 | 2004 | 8 | 0.060 |
Why?
|
| Mutation | 1 | 2013 | 2588 | 0.060 |
Why?
|
| Genome, Viral | 1 | 2025 | 130 | 0.060 |
Why?
|
| Poly I-C | 1 | 2024 | 76 | 0.050 |
Why?
|
| Transcriptome | 2 | 2021 | 386 | 0.050 |
Why?
|
| Primaquine | 1 | 2023 | 4 | 0.050 |
Why?
|
| Chloroquine | 1 | 2023 | 61 | 0.050 |
Why?
|
| Rabbits | 1 | 2024 | 331 | 0.050 |
Why?
|
| Epitopes | 1 | 2024 | 294 | 0.050 |
Why?
|
| Down-Regulation | 1 | 2004 | 318 | 0.050 |
Why?
|
| Biology | 1 | 2022 | 26 | 0.050 |
Why?
|
| Convalescence | 1 | 2022 | 18 | 0.050 |
Why?
|
| Cross Protection | 1 | 2021 | 6 | 0.050 |
Why?
|
| Mucins | 1 | 2022 | 26 | 0.050 |
Why?
|
| Neutralization Tests | 1 | 2022 | 121 | 0.050 |
Why?
|
| ROC Curve | 1 | 2022 | 280 | 0.050 |
Why?
|
| N-Acetylneuraminic Acid | 1 | 2022 | 54 | 0.050 |
Why?
|
| Receptors, Cell Surface | 1 | 2004 | 430 | 0.050 |
Why?
|
| Glycolysis | 1 | 2021 | 58 | 0.050 |
Why?
|
| Phagosomes | 1 | 2021 | 54 | 0.040 |
Why?
|
| Butyrophilins | 1 | 2021 | 3 | 0.040 |
Why?
|
| Immunological Synapses | 1 | 2021 | 10 | 0.040 |
Why?
|
| Primary Cell Culture | 1 | 2021 | 78 | 0.040 |
Why?
|
| Transcription Factors | 1 | 2009 | 1507 | 0.040 |
Why?
|
| Viral Load | 1 | 2021 | 231 | 0.040 |
Why?
|
| Apoptosis | 2 | 2019 | 1071 | 0.040 |
Why?
|
| Sirolimus | 1 | 2021 | 92 | 0.040 |
Why?
|
| Community-Institutional Relations | 1 | 2020 | 37 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2022 | 276 | 0.040 |
Why?
|
| Galactosyltransferases | 1 | 2020 | 16 | 0.040 |
Why?
|
| Mammals | 1 | 2022 | 218 | 0.040 |
Why?
|
| Personal Protective Equipment | 1 | 2020 | 33 | 0.040 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2021 | 121 | 0.040 |
Why?
|
| Chemokine CCL5 | 1 | 2020 | 33 | 0.040 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2020 | 42 | 0.040 |
Why?
|
| Receptors, Chemokine | 1 | 2020 | 33 | 0.040 |
Why?
|
| Boston | 1 | 2021 | 250 | 0.040 |
Why?
|
| Emulsions | 1 | 2023 | 472 | 0.040 |
Why?
|
| Superoxide Dismutase | 1 | 2021 | 227 | 0.040 |
Why?
|
| Adenosine Triphosphate | 1 | 2021 | 291 | 0.040 |
Why?
|
| Receptors, CCR2 | 1 | 2019 | 13 | 0.040 |
Why?
|
| Bacterial Proteins | 1 | 2025 | 769 | 0.040 |
Why?
|
| Circadian Clocks | 1 | 2020 | 47 | 0.040 |
Why?
|
| Global Health | 1 | 2020 | 181 | 0.040 |
Why?
|
| Infection Control | 1 | 2020 | 105 | 0.040 |
Why?
|
| Myocarditis | 1 | 2020 | 66 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-rel | 1 | 2018 | 16 | 0.040 |
Why?
|
| Cytoplasm | 1 | 2020 | 277 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 180 | 0.040 |
Why?
|
| Consensus | 1 | 2019 | 226 | 0.040 |
Why?
|
| Ligands | 1 | 2019 | 417 | 0.040 |
Why?
|
| Stroke Volume | 1 | 2020 | 331 | 0.040 |
Why?
|
| Gene Expression | 1 | 2021 | 837 | 0.040 |
Why?
|
| Gene Ontology | 1 | 2017 | 38 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2020 | 316 | 0.030 |
Why?
|
| Virulence | 1 | 2017 | 195 | 0.030 |
Why?
|
| Electrocardiography | 1 | 2020 | 553 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 2020 | 466 | 0.030 |
Why?
|
| Leishmania mexicana | 1 | 2016 | 7 | 0.030 |
Why?
|
| Lung | 1 | 2021 | 937 | 0.030 |
Why?
|
| Vacuoles | 1 | 2016 | 26 | 0.030 |
Why?
|
| Heme | 1 | 2016 | 29 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2021 | 2446 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2019 | 1113 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2016 | 207 | 0.030 |
Why?
|
| Immune System Phenomena | 1 | 2015 | 3 | 0.030 |
Why?
|
| Nitric Oxide | 1 | 2016 | 173 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2016 | 516 | 0.030 |
Why?
|
| Histones | 1 | 2018 | 481 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2018 | 384 | 0.030 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2014 | 10 | 0.030 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2017 | 639 | 0.030 |
Why?
|
| Genes, Essential | 1 | 2013 | 19 | 0.030 |
Why?
|
| Genetic Complementation Test | 1 | 2013 | 63 | 0.030 |
Why?
|
| Chromosomes, Insect | 1 | 2013 | 8 | 0.030 |
Why?
|
| Synteny | 1 | 2013 | 23 | 0.030 |
Why?
|
| Insecticide Resistance | 1 | 2013 | 10 | 0.030 |
Why?
|
| CARD Signaling Adaptor Proteins | 1 | 2013 | 67 | 0.030 |
Why?
|
| Animals, Genetically Modified | 1 | 2014 | 289 | 0.030 |
Why?
|
| Immunity, Humoral | 1 | 2013 | 40 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2020 | 3257 | 0.030 |
Why?
|
| Insect Proteins | 1 | 2013 | 80 | 0.030 |
Why?
|
| Antibody Specificity | 1 | 2013 | 102 | 0.030 |
Why?
|
| Drosophila | 1 | 2016 | 430 | 0.030 |
Why?
|
| Molecular Sequence Annotation | 1 | 2013 | 65 | 0.030 |
Why?
|
| Infant | 1 | 2018 | 1629 | 0.030 |
Why?
|
| Insecticides | 1 | 2013 | 44 | 0.030 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2013 | 150 | 0.030 |
Why?
|
| Lysosomal-Associated Membrane Protein 1 | 1 | 2012 | 6 | 0.020 |
Why?
|
| DNA Transposable Elements | 1 | 2013 | 136 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2013 | 296 | 0.020 |
Why?
|
| Endoplasmic Reticulum | 1 | 2013 | 173 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2013 | 308 | 0.020 |
Why?
|
| Myocytes, Cardiac | 1 | 2012 | 96 | 0.020 |
Why?
|
| Interferon Regulatory Factor-7 | 1 | 2011 | 33 | 0.020 |
Why?
|
| Receptor, Interferon alpha-beta | 1 | 2011 | 52 | 0.020 |
Why?
|
| Interferon Regulatory Factor-3 | 1 | 2011 | 95 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2013 | 382 | 0.020 |
Why?
|
| Evolution, Molecular | 1 | 2013 | 312 | 0.020 |
Why?
|
| Risk Factors | 1 | 2020 | 5297 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2014 | 1181 | 0.020 |
Why?
|